CDER Outlines Priorities For Drug Development
While the US Center for Drug Evaluation and Research had accomplished much in 1995, its director Janet Woodcock told a Food and Drug Law Institute meeting last month that challenges in the area of methodologic research and information management remain.
The CDER, she said, will continue to work with the large amount of data it has to extract information on how drug development could be improved, while continuing to improve the infrastructure for information management. She added: the Center's priorities for fiscal 1996 include: - exceeding use fee goals again; - implementing the CDER reorganization now in place so it achieves the planned objectives; - continuing to improve the management of the Center; - and implementing information management initiatives.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze